VRTX — VERTEX PHARMACEUTICALS INC / MA
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on VRTX
| date | signal | measured base rate |
|---|---|---|
| 2026-08-11 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-08-10 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-08-10 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-09 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-06 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-29 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-21 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Grant or award | 8.3K | 0.00 | 0 |
| 2026-07-21 | Sachdev Amit EVP Chief Patient & Ext Af Off | Grant or award | 8.3K | 0.00 | 0 |
| 2026-07-02 | McKechnie Duncan EVP, Chief Commercial Officer | Open-market sale 10b5-1 plan | 1.5K | 519.00 | 799.8K |
| 2026-07-02 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Open-market sale 10b5-1 plan | 1.5K | 524.99 | 787.5K |
| 2026-07-01 | Liu Joy EVP and Chief Legal Officer | Open-market sale 10b5-1 plan | 828 | 502.71 | 416.2K |
| 2026-06-26 | Bozic Carmen EVP and CMO | Open-market sale 10b5-1 plan | 596 | 482.50 | 287.6K |
| 2026-06-18 | Bozic Carmen EVP and CMO | Open-market sale 10b5-1 plan | 1.0K | 462.17 | 471.4K |
| 2026-06-15 | Bozic Carmen EVP and CMO | Open-market sale 10b5-1 plan | 4.1K | 450.00 | 1.8M |
| 2026-06-05 | Bozic Carmen EVP and CMO | Open-market sale 10b5-1 plan | 1.7K | 450.00 | 785.2K |
| 2026-06-01 | Liu Joy EVP and Chief Legal Officer | Open-market sale 10b5-1 plan | 828 | 439.91 | 364.2K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Capital World Investors | 11.3B | 25.4M |
| BlackRock, Inc. | 10.7B | 24.0M |
| Capital Research Global Investors | 9.4B | 21.1M |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.4B | 16.5M |
| STATE STREET CORP | 5.2B | 11.7M |
| JPMORGAN CHASE & CO | 3.1B | 7.0M |
| GEODE CAPITAL MANAGEMENT, LLC | 2.7B | 6.1M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.3B | 5.1M |
| Capital International Investors | 2.3B | 5.1M |
| LOOMIS SAYLES & CO L P | 1.8B | 4.0M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 10-Q | 2026-08-04 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-03 | 2026-08-03 | on EDGAR ↗ |
| 4 | 2026-07-23 | 2026-07-21 | on EDGAR ↗ |
| 4 | 2026-07-23 | 2026-07-21 | on EDGAR ↗ |
| 4 | 2026-07-17 | 2026-07-15 | on EDGAR ↗ |
| 4 | 2026-07-17 | 2026-07-15 | on EDGAR ↗ |
| 4 | 2026-07-07 | 2026-07-02 | on EDGAR ↗ |
| 4 | 2026-07-07 | 2026-07-02 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Is Vertex Pharmaceuticals (VRTX) Cheap Following Its Raised 2026 Revenue Guidance? - simplywall.st · 2026-08-22 · simplywall.st
- Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? · 2026-08-21
- Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’ · 2026-08-21 · benzinga
- Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead · 2026-08-20
- CNBC Halftime Report Final Trades: ServiceNow, Uber Technologies, Vertex Pharmaceuticals · 2026-08-20 · benzinga
- Why is Vertex Pharmaceuticals stock surging today? · 2026-08-10
Ask the AI about VRTX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →